Home > Insider Trading > Filing (0001209191-17-006676)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1640455	Jounce Therapeutics Inc.	JNCE	Pharmaceutical Preparations (2834)	DE

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
816284	Celgene Corp /De/	86 Morris Avenue Summit NJ 07901		No	No	Yes	No
1661486	Celgene Switzerland Llc	Aon House 30 Woodbourne Avenue Pembroke D0 HM 08		No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2017-02-01	2,831,463	$0.00	2,831,463	No	4	C	Direct
Common Stock	Acquisiton	2017-02-01	625,000	$16.00	3,456,463	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Direct
No	4	P	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series B-1 Preferred Stock	Disposition	2017-02-01	10,448,100	$0.00	2,831,463	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Direct

Footnotes

Upon closing of the Issuer's initial public offering, each share of Series B-1 Preferred Stock automatically converted into 0.271 share of Common Stock without payment of further consideration. The shares had no expiration date.
These shares are owned directly by Celgene Switzerland LLC, a wholly-owned subsidiary of Celgene Corporation ("Celgene"), and Celgene has the power to vote, acquire, hold and dispose of all shares. Celgene disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein.